Edition:
India

Onconova Therapeutics Inc (ONTX.OQ)

ONTX.OQ on NASDAQ Stock Exchange Capital Market

1.61USD
8:44pm IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.61
Open
$1.62
Day's High
$1.65
Day's Low
$1.61
Volume
7,971
Avg. Vol
50,650
52-wk High
$3.88
52-wk Low
$1.21

Chart for

About

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to... (more)

Overall

Beta: 0.14
Market Cap(Mil.): $17.24
Shares Outstanding(Mil.): 9.85
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.62
EPS (TTM): -- -- --
ROI: -- 14.89 10.61
ROE: -- 16.37 14.21

BRIEF-Onconova Says Moving Forward With Pivotal Late-Stage Trial

* ONCONOVA MOVING FORWARD WITH PHASE 3 INSPIRE PIVOTAL TRIAL WITH INCREASED SAMPLE SIZE FOLLOWING PROMISING INTERIM ANALYSIS

17 Jan 2018

BRIEF-Onconova Therapeutics Says Entered Into Cooperative Research And Development Agreement With NCI

* ONCONOVA THERAPEUTICS SAYS ENTERED INTO COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH NATIONAL CANCER INSTITUTE

04 Jan 2018

BRIEF-Onconova Therapeutics Announces License And Collaborative Development Agreement With Hanx Biopharma

* ONCONOVA THERAPEUTICS ANNOUNCES LICENSE AND COLLABORATIVE DEVELOPMENT AGREEMENT WITH HANX BIOPHARMACEUTICALS FOR ON 123300, A DUAL INHIBITOR OF CDK4/6 + ARK5

19 Dec 2017

BRIEF-Onconova Therapeutics files for mixed shelf offering of upto $84.5 mln

* Onconova Therapeutics Inc files for mixed shelf offering of upto $84.5 million- SEC filing‍​ Source text: (http://bit.ly/2AiGwl1) Further company coverage:

21 Nov 2017

BRIEF-Onconova Therapeutics announces data on improved formulation of Rigosertib and next-generation CDK4/6 inhibitor

* Onconova Therapeutics announces data on improved formulation of Rigosertib and next-generation CDK4/6 inhibitor at 2017 American Association Of Pharmaceutical Scientists annual meeting Source text for Eikon: Further company coverage:

16 Nov 2017

BRIEF-Onconova Therapeutics prices public offering

* Onconova Therapeutics announces pricing of public offering of common stock

10 Nov 2017

BRIEF-Onconova Therapeutics reports Q3 revenue $100,000

* Onconova Therapeutics, Inc. reports business highlights and third quarter 2017 financial results

09 Nov 2017

BRIEF-Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics

* Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics to develop new phospholipid drug conjugates

21 Sep 2017

BRIEF-Onconova Therapeutics reports qtrly net loss per share of $0.29

* Onconova Therapeutics, Inc. reports recent business highlights and second quarter 2017 financial results

15 Aug 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.66 -0.27
Roche Holding Ltd. (ROG.S) CHF236.65 +0.85
Roche Holding Ltd. (RO.S) CHF240.20 +1.80
GlaxoSmithKline plc (GSK.L) 1,375.60 +20.40
Isu Abxis Co Ltd (086890.KQ) ₩12,600.00 +250.00
Salix Pharmaceuticals, Ltd. (SLXP.OQ) -- --

Earnings vs. Estimates